Real time Form 13D and 13G transaction reports:
- Schedule 13D must be filed within ten days after a person or an organization acquires beneficial ownership of more than 5% of a voting class of a company's equity securities.
- Due to inconsistent filing format, it is highly recommended that you read the orignal filing form.
- Shares have beem adjusted for stock split.
"Insiders might sell their shares for any number of reasons, but they buy them for only one: they think the price will rise"
- Peter Lynch
What is insider trading>>
- Peter Lynch
What is insider trading>>
| Reported DateTime | Transaction Date | Type | Company Symbol | Filed By Symbol | Shares Owned % Owned | Shares Vs. Prev Report | View |
| 2025-10-21 08:00 am Sale | 2025-07-14 | 13G | Innate Pharma S.A. IPHA | Novo Nordisk A/S | 8,895,649 9.650% | -921,897 (-9.39%) | Filing History |
| 2025-04-23 7:39 pm Purchase | 2025-03-31 | 13G | Novo Nordisk A/S NVO | BlackRock Inc. BLK | 177,801,601 5.200% | 177,801,601 (New Position) | Filing History |
| 2024-02-06 3:14 pm Purchase | 2023-12-31 | 13G | Novo Nordisk A/S NVO | BlackRock Inc. BLK | 236,598,124 6.900% | 122,845,158 (+107.99%) | Filing |
| 2023-02-23 5:06 pm Sale | 2022-12-31 | 13G | Novo Nordisk A/S NVO | BlackRock Inc. BLK | 227,505,932 6.500% | -19,908,398 (-8.05%) | Filing |
| 2022-01-31 5:59 pm Purchase | 2021-12-31 | 13G | Novo Nordisk A/S NVO | BlackRock Inc. BLK | 247,414,330 7.000% | 16,539,332 (+7.16%) | Filing |
| 2021-01-29 5:21 pm Purchase | 2020-12-31 | 13G | Novo Nordisk A/S NVO | BlackRock Inc. BLK | 230,874,998 6.400% | 14,917,942 (+6.91%) | Filing |